Our finding in this current study demonstrated that when syndecan-1 is positive, a higher expression of ANXA7 further decreases survival rate, highlighting the importance of ANXA7 as an important biomarker along with syndecan-1 for the prediction of survival rates in prostate cancer patients. Here, SDC1 is linked to prostate cancer.